Nlrc4-associated Macrophage Activation Syndrome
📧 Sign up to get email alerts when something new happens for Nlrc4-associated Macrophage Activation Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency [Phase 3]
A Phase 3 trial of tadekinig alfa for NLRC4-associated macrophage activation syndrome (NLRC4-MAS) and XIAP deficiency has completed with res…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension [Phase 3]
A Phase 3 open-label extension of tadekinig alfa for XIAP deficiency and NLRC4-associated macrophage activation syndrome has completed.